Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial

12/27/2020 | 08:48pm EST


© MT Newswires 2020
All news about ASTELLAS PHARMA INC.
09:25aASTELLAS PHARMA  : Notice Regarding Continuation of the Performance-linked Stock..
AQ
02/26ASTELLAS PHARMA  : Notice Regarding Continuation of the Performance-linked Stock..
PU
02/24PRESS RELEASE  : Creative Balloons closes EUR15 million growth financing and app..
DJ
02/22ASTELLAS PHARMA  : Announces Positive Topline Results from Two Phase 3 Pivotal G..
AQ
02/19ASTELLAS PHARMA  : and Seagen Announce Submission of Two Supplemental Biologics ..
AQ
02/15SEAGEN  : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adv..
AQ
02/15ASTELLAS PHARMA  : and Seagen Announce Presentation of Results from PADCEV Pivot..
AQ
02/09Japan shares edge higher driven by Honda's upbeat earnings outlook
RE
02/04ASTELLAS PHARMA  : XOSPATA Receives Conditional Approval by China's National Med..
AQ
02/04ASTELLAS PHARMA  : Announces Management Structure
AQ
More news
Financials
Sales 2021 1 258 B 11 780 M 11 780 M
Net income 2021 176 B 1 648 M 1 648 M
Net cash 2021 440 B 4 117 M 4 117 M
P/E ratio 2021 17,7x
Yield 2021 2,46%
Capitalization 3 177 B 29 797 M 29 751 M
EV / Sales 2021 2,18x
EV / Sales 2022 2,02x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 261,54 JPY
Last Close Price 1 710,50 JPY
Spread / Highest target 110%
Spread / Average Target 32,2%
Spread / Lowest Target -3,54%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Keiko Yamagami Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.7.31%29 155
JOHNSON & JOHNSON0.69%416 541
ROCHE HOLDING AG-3.58%280 845
NOVARTIS AG-6.53%194 250
ABBVIE INC.0.55%190 256
PFIZER INC.-9.02%186 852